Last reviewed · How we verify
Infective endocarditis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vancocin | vancomycin | ANI Pharmaceuticals | Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- ANI Pharmaceuticals · 1 drug in Infective endocarditis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infective endocarditis:
- Infective endocarditis treatment updates — RSS
- Infective endocarditis treatment updates — Atom
- Infective endocarditis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infective endocarditis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infective-endocarditis. Accessed 2026-06-10.
Related
- Infective endocarditis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing